Literature DB >> 27041705

Patient and medication-related factors associated with hospital-acquired hyponatremia in patients hospitalized from heart failure.

S Saepudin1,2, Patrick A Ball3, Hana Morrissey3.   

Abstract

Background Hyponatremia has been known as an important predictor of clinical outcomes in patients with heart failure (HF). While information on hyponatremia in patients with HF has been available abundantly, information on factors associated with increased risk of developing hospital-acquired hyponatremia (HAH) is still limited. Objective To identify patients and medication-related factors associated with HAH in patients hospitalized from HF. Setting Fatmawati Hospital in Jakarta, Indonesia. Methods This is a nested case-control study with patients developing HAH served as case group and each patient in case group was matched by age and gender to three patients in control group. Patients included in this study are patients hospitalized from HF, and coded with I.50 according to ICD-10, during 2011-2013 at Fatmawati Hospital in Jakarta, Indonesia. Information retrieved from patients' medical records included demographic profiles, vital signs and symptoms at admission, past medical history, medication during hospitalization and clinical chemistry laboratory records. Multivariable logistic regression analysis was performed to find out patient and treatment-related factors associated with the development of HAH. Main outcome measures Patients and medication related factors having significant association with HAH. Results Four hundreds sixty-four patients were included in this study and 45 of them (9.7 %) met criteria of developing HAH so then, accordingly, 135 patients were selected as controls. 36 patient- and 22 treatment-related factors were analyzed in univariate logistic regression resulted in 20 factors having p value <0.2 and were included in multivariable logistic regression analysis. Final factors showing significant association with HAH are presence of ascites at admission (odds ratio = 4.7; 95 % confidence interval 1.9-11.5) and administration of amiodarone (3.2; 1.3-7.4) and heparin (3.1; 1.2-7.3) during hospital stay. Conclusion Presence of ascites at admission was found as patient-related factors associated with HAH in this study. In addition, administration of amiodarone and heparin during hospital stay were found as medication-related factors associated with HAH in patients hospitalized from HF.

Entities:  

Keywords:  Heart failure; Hyponatremia; Indonesia; Serum sodium level

Mesh:

Substances:

Year:  2016        PMID: 27041705     DOI: 10.1007/s11096-016-0296-3

Source DB:  PubMed          Journal:  Int J Clin Pharm


  29 in total

1.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  J Am Coll Cardiol       Date:  2013-06-05       Impact factor: 24.094

Review 2.  The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists.

Authors:  Jalal K Ghali; S William Tam
Journal:  J Card Fail       Date:  2010-02-20       Impact factor: 5.712

Review 3.  Amiodarone -- waxed and waned and waxed again.

Authors:  S A Doggrell
Journal:  Expert Opin Pharmacother       Date:  2001-11       Impact factor: 3.889

4.  Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management.

Authors:  Ewout J Hoorn; Jan Lindemans; Robert Zietse
Journal:  Nephrol Dial Transplant       Date:  2005-09-02       Impact factor: 5.992

Review 5.  Clinical challenge of hyponatremia in heart failure.

Authors:  Paul J Hauptman
Journal:  J Hosp Med       Date:  2012-04       Impact factor: 2.960

6.  Hyponatremia treatment guidelines 2007: expert panel recommendations.

Authors:  Joseph G Verbalis; Stephen R Goldsmith; Arthur Greenberg; Robert W Schrier; Richard H Sterns
Journal:  Am J Med       Date:  2007-11       Impact factor: 4.965

7.  Hyponatremia and in-hospital mortality in patients admitted for heart failure (from the ATTEND registry).

Authors:  Naoki Sato; Mihai Gheorghiade; Katsuya Kajimoto; Ryo Munakata; Yuichiro Minami; Masayuki Mizuno; Toshiyuki Aokage; Kuniya Asai; Yasushi Sakata; Dai Yumino; Kyoichi Mizuno; Teruo Takano
Journal:  Am J Cardiol       Date:  2013-01-09       Impact factor: 2.778

8.  Outcome differences in community- versus hospital-acquired hyponatremia in patients with a diagnosis of heart failure.

Authors:  Dmitry Y Shchekochikhin; Robert W Schrier; JoAnn Lindenfeld; Lori Lyn Price; Bertrand L Jaber; Nicolaos E Madias
Journal:  Circ Heart Fail       Date:  2013-03-19       Impact factor: 8.790

Review 9.  The treatment of hyponatremia.

Authors:  Richard H Sterns; Sagar U Nigwekar; John Kevin Hix
Journal:  Semin Nephrol       Date:  2009-05       Impact factor: 5.299

10.  Current treatment practice and outcomes. Report of the hyponatremia registry.

Authors:  Arthur Greenberg; Joseph G Verbalis; Alpesh N Amin; Volker R Burst; Joseph A Chiodo; Jun R Chiong; Joseph F Dasta; Keith E Friend; Paul J Hauptman; Alessandro Peri; Samuel H Sigal
Journal:  Kidney Int       Date:  2015-02-11       Impact factor: 10.612

View more
  1 in total

1.  Hyponatremia and risk factors for death in human visceral leishmaniasis: new insights from a cross-sectional study in Brazil.

Authors:  Elizabeth De Francesco Daher; Douglas de Sousa Soares; Sérgio Luiz Arruda Parente Filho; Gdayllon Cavalcante Meneses; Tainá Veras de Sandes Freitas; Tacyano Tavares Leite; Geraldo Bezerra da Silva Junior
Journal:  BMC Infect Dis       Date:  2017-02-23       Impact factor: 3.090

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.